The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas

Yoshihiro Miyasaka, Eishi Nagai, Hiroshi Yamaguchi, Kei Fujii, Takahiro Inoue, Kenoki Ohuchida, Tomomi Yamada, Kazuhiro Mizumoto, Masao Tanaka, Masazumi Tsuneyoshi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Purpose: Intraductal papillary mucinous neoplasms (IPMN) are known to show a transition from adenoma to carcinoma accompanied by several molecular abnormalities. ATM-Chk2-p53 DNA damage checkpoint activation, which is involved in prevention of the progression of several tumors, was analyzed to evaluate the role of the DNA damage checkpoint in the progression of IPMNs. Experimental Design: One hundred and twenty-eight IPMNs were classified into four groups (intraductal papillary mucinous adenoma, borderline IPMN, noninvasive intraductal papillary mucinous carcinoma, and invasive intraductal papillary mucinous carcinoma) and stained immunohistochemically using antibody for Thr68-phosphorylated Chk2. Expression of ATM, Chk2, and p21 WAF1 and accumulation of p53 were also analyzed. Results: Chk2 phosphorylationwas shownin all adenomas and showed a significant decreasing trend with the progression of atypia (P < 0.0001 by the Cochran-Armitage test for trend). Expression of p21WAF1 also exhibited a decreasing tendency (P < 0.0001), reflecting DNA damage checkpoint inactivation. p53 accumulation was mostly detected in malignant IPMNs. It was suggested that the DNA damage checkpoint provides a selective pressure for p53 mutation. Conclusion: Our findings indicate that DNA damage checkpoint activation occurs in the early stage of IPMNs and prevents their progression. It is suggested that disturbance of the DNA damage checkpoint pathway due to Chk2 inactivation or p53 mutation contributes to the carcinogenesis of IPMNs.

Original languageEnglish
Pages (from-to)4371-4377
Number of pages7
JournalClinical Cancer Research
Volume13
Issue number15
DOIs
Publication statusPublished - Aug 1 2007

Fingerprint

Pancreatic Neoplasms
DNA Damage
Adenoma
Mucinous Adenocarcinoma
Carcinoma, Intraductal, Noninfiltrating
Papillary Carcinoma
Neoplasms
Mutation
Carcinogenesis
Research Design
Carcinoma
Antibodies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas. / Miyasaka, Yoshihiro; Nagai, Eishi; Yamaguchi, Hiroshi; Fujii, Kei; Inoue, Takahiro; Ohuchida, Kenoki; Yamada, Tomomi; Mizumoto, Kazuhiro; Tanaka, Masao; Tsuneyoshi, Masazumi.

In: Clinical Cancer Research, Vol. 13, No. 15, 01.08.2007, p. 4371-4377.

Research output: Contribution to journalArticle

Miyasaka, Y, Nagai, E, Yamaguchi, H, Fujii, K, Inoue, T, Ohuchida, K, Yamada, T, Mizumoto, K, Tanaka, M & Tsuneyoshi, M 2007, 'The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas', Clinical Cancer Research, vol. 13, no. 15, pp. 4371-4377. https://doi.org/10.1158/1078-0432.CCR-07-0032
Miyasaka, Yoshihiro ; Nagai, Eishi ; Yamaguchi, Hiroshi ; Fujii, Kei ; Inoue, Takahiro ; Ohuchida, Kenoki ; Yamada, Tomomi ; Mizumoto, Kazuhiro ; Tanaka, Masao ; Tsuneyoshi, Masazumi. / The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 15. pp. 4371-4377.
@article{369661a03b7d47e3b5902bf5030fc214,
title = "The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas",
abstract = "Purpose: Intraductal papillary mucinous neoplasms (IPMN) are known to show a transition from adenoma to carcinoma accompanied by several molecular abnormalities. ATM-Chk2-p53 DNA damage checkpoint activation, which is involved in prevention of the progression of several tumors, was analyzed to evaluate the role of the DNA damage checkpoint in the progression of IPMNs. Experimental Design: One hundred and twenty-eight IPMNs were classified into four groups (intraductal papillary mucinous adenoma, borderline IPMN, noninvasive intraductal papillary mucinous carcinoma, and invasive intraductal papillary mucinous carcinoma) and stained immunohistochemically using antibody for Thr68-phosphorylated Chk2. Expression of ATM, Chk2, and p21 WAF1 and accumulation of p53 were also analyzed. Results: Chk2 phosphorylationwas shownin all adenomas and showed a significant decreasing trend with the progression of atypia (P < 0.0001 by the Cochran-Armitage test for trend). Expression of p21WAF1 also exhibited a decreasing tendency (P < 0.0001), reflecting DNA damage checkpoint inactivation. p53 accumulation was mostly detected in malignant IPMNs. It was suggested that the DNA damage checkpoint provides a selective pressure for p53 mutation. Conclusion: Our findings indicate that DNA damage checkpoint activation occurs in the early stage of IPMNs and prevents their progression. It is suggested that disturbance of the DNA damage checkpoint pathway due to Chk2 inactivation or p53 mutation contributes to the carcinogenesis of IPMNs.",
author = "Yoshihiro Miyasaka and Eishi Nagai and Hiroshi Yamaguchi and Kei Fujii and Takahiro Inoue and Kenoki Ohuchida and Tomomi Yamada and Kazuhiro Mizumoto and Masao Tanaka and Masazumi Tsuneyoshi",
year = "2007",
month = "8",
day = "1",
doi = "10.1158/1078-0432.CCR-07-0032",
language = "English",
volume = "13",
pages = "4371--4377",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas

AU - Miyasaka, Yoshihiro

AU - Nagai, Eishi

AU - Yamaguchi, Hiroshi

AU - Fujii, Kei

AU - Inoue, Takahiro

AU - Ohuchida, Kenoki

AU - Yamada, Tomomi

AU - Mizumoto, Kazuhiro

AU - Tanaka, Masao

AU - Tsuneyoshi, Masazumi

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Purpose: Intraductal papillary mucinous neoplasms (IPMN) are known to show a transition from adenoma to carcinoma accompanied by several molecular abnormalities. ATM-Chk2-p53 DNA damage checkpoint activation, which is involved in prevention of the progression of several tumors, was analyzed to evaluate the role of the DNA damage checkpoint in the progression of IPMNs. Experimental Design: One hundred and twenty-eight IPMNs were classified into four groups (intraductal papillary mucinous adenoma, borderline IPMN, noninvasive intraductal papillary mucinous carcinoma, and invasive intraductal papillary mucinous carcinoma) and stained immunohistochemically using antibody for Thr68-phosphorylated Chk2. Expression of ATM, Chk2, and p21 WAF1 and accumulation of p53 were also analyzed. Results: Chk2 phosphorylationwas shownin all adenomas and showed a significant decreasing trend with the progression of atypia (P < 0.0001 by the Cochran-Armitage test for trend). Expression of p21WAF1 also exhibited a decreasing tendency (P < 0.0001), reflecting DNA damage checkpoint inactivation. p53 accumulation was mostly detected in malignant IPMNs. It was suggested that the DNA damage checkpoint provides a selective pressure for p53 mutation. Conclusion: Our findings indicate that DNA damage checkpoint activation occurs in the early stage of IPMNs and prevents their progression. It is suggested that disturbance of the DNA damage checkpoint pathway due to Chk2 inactivation or p53 mutation contributes to the carcinogenesis of IPMNs.

AB - Purpose: Intraductal papillary mucinous neoplasms (IPMN) are known to show a transition from adenoma to carcinoma accompanied by several molecular abnormalities. ATM-Chk2-p53 DNA damage checkpoint activation, which is involved in prevention of the progression of several tumors, was analyzed to evaluate the role of the DNA damage checkpoint in the progression of IPMNs. Experimental Design: One hundred and twenty-eight IPMNs were classified into four groups (intraductal papillary mucinous adenoma, borderline IPMN, noninvasive intraductal papillary mucinous carcinoma, and invasive intraductal papillary mucinous carcinoma) and stained immunohistochemically using antibody for Thr68-phosphorylated Chk2. Expression of ATM, Chk2, and p21 WAF1 and accumulation of p53 were also analyzed. Results: Chk2 phosphorylationwas shownin all adenomas and showed a significant decreasing trend with the progression of atypia (P < 0.0001 by the Cochran-Armitage test for trend). Expression of p21WAF1 also exhibited a decreasing tendency (P < 0.0001), reflecting DNA damage checkpoint inactivation. p53 accumulation was mostly detected in malignant IPMNs. It was suggested that the DNA damage checkpoint provides a selective pressure for p53 mutation. Conclusion: Our findings indicate that DNA damage checkpoint activation occurs in the early stage of IPMNs and prevents their progression. It is suggested that disturbance of the DNA damage checkpoint pathway due to Chk2 inactivation or p53 mutation contributes to the carcinogenesis of IPMNs.

UR - http://www.scopus.com/inward/record.url?scp=34547686211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547686211&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0032

DO - 10.1158/1078-0432.CCR-07-0032

M3 - Article

C2 - 17671118

AN - SCOPUS:34547686211

VL - 13

SP - 4371

EP - 4377

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 15

ER -